挖掘阿尔茨海默病互动体,宏分子复合体和药物发现途径
Kalpana Panneerselvam1, Krishna Kumar Tiwari1, Luana Licata2
1European Bioinformatics Institute (EMBL-EBI), European Molecular Biology Laboratory, Hinxton, Cambridge, UK.
Proteomics
|August 26, 2025
概括
这项研究将阿尔茨海默病的突变映射到蛋白相互作用和调节网络上. 这些发现揭示了阿尔茨海默病中精准医学的破坏性途径和潜在的治疗目标.
科学领域:
- 神经科学
- 分子生物学
- 遗传学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,导致痴呆症,目前尚无治疗方法.
- 了解AD的分子基础对于开发有效治疗至关重要.
- 将基因变异映射到分子相互作用提供了疾病途径的洞察力.
研究的目的:
- 确定阿尔茨海默病相关突变如何改变蛋白质相互作用和调节网络.
- 在脑组织中发现变异特异性途径.
- 通过分析粉样蛋白前体蛋白 (APP) 的蛋白相互作用体来探索治疗点.
主要方法:
- 在精心策划的AD数据集上进行差异互动组分析.
- 在与大脑相关的组织中绘制变异特异性蛋白相互作用.
- 微RNA (miRNA) 中介调节的反应体丰富分析和整合.
主要成果:
- 鉴定了因AD突变而导致的暂时和稳定蛋白相互作用的变化.
- 在宏分子组合和扰乱路径中发现了变异特异性干扰.
- 对关键的AD基因进行了miRNA介导的后转录控制,并确定了基于APP相互作用的治疗点.
结论:
- 一个多层策略为了解AD分子网络提供了一个框架.
- 这种方法有助于确定阿尔茨海默病的精确治疗策略.
- 将基因变异映射到交互体中可以提高我们对阿尔茨海默病变的理解.
相关概念视频
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
Protein Networks
4.1K
An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
4.1K
Drug Discovery: Overview
8.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.7K
Protein-protein Interfaces
13.2K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
13.2K
Amyloid Fibrils
9.9K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.9K


